TriangleNCT00703820 · OUTCOME
Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Followed by Natural Killer Cell Transplantation.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 3 years after completion of therapy
What was measured
Kaplan-Meier estimate of the probability of being alive and free of relapse or second malignancy three years after protocol enrollment
Analysis population: Randomized patients who received NK cell therapy after chemotherapy
Groups in this outcome
Cytarabine+Daunorubicin+Etoposide
Patients received Cytarabine + Daunorubicin + Etoposide as their first course of chemotherapy. Subsequent therapy is risk-adapted.
Clofarabine+Cytarabine
Patients received Clofarabine + Cytarabine as their first course of chemotherapy. Subsequent therapy is risk- adapted.
| Group | Source count |
|---|---|
| Cytarabine+Daunorubicin+Etoposide | 9 |
| Clofarabine+Cytarabine | 9 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cytarabine+Daunorubicin+Etoposide | 55.6 | Not reported | 31.0 | 99.7 | Not reported |
| Clofarabine+Cytarabine | 77.8 | Not reported | 54.9 | 100.0 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 31.0
- upper Limit
- 99.7
- value
- 55.6
- group Id
- OG001
- lower Limit
- 54.9
- upper Limit
- 100.0
- value
- 77.8
- denoms
- counts
- group Id
- OG000
- value
- 9
- group Id
- OG001
- value
- 9
- units
- Participants
- description
- Kaplan-Meier estimate of the probability of being alive and free of relapse or second malignancy three years after protocol enrollment
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients received Cytarabine + Daunorubicin + Etoposide as their first course of chemotherapy. Subsequent therapy is risk-adapted.
- id
- OG000
- title
- Cytarabine+Daunorubicin+Etoposide
- description
- Patients received Clofarabine + Cytarabine as their first course of chemotherapy. Subsequent therapy is risk- adapted.
- id
- OG001
- title
- Clofarabine+Cytarabine
- param Type
- NUMBER
- population Description
- Randomized patients who received NK cell therapy after chemotherapy
- reporting Status
- POSTED
- time Frame
- 3 years after completion of therapy
- title
- Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Followed by Natural Killer Cell Transplantation.
- type
- SECONDARY
- unit Of Measure
- Percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice